FDA Grants Orphan Drug Designation to CTD402, an Off‑the‑Shelf Anti‑CD7 CAR‑T Therapy, for Rare T‑Cell Leukemias and Lymphomas
The Food and Drug Administration (FDA) has granted orphan drug designation to CTD402, an investigational allogeneic anti‑CD7 CAR‑T cell therapy from Imviva Biotech, for the treatment of patients with relapsed or refractory T‑cell acute lymphoblastic leukemia (T‑ALL) and lymphoblastic lymphoma
